On June 15, 2026, Alkermes plc announced that the U.S. Food and Drug Administration granted orphan drug designation to alixorexton for treating idiopathic hypersomnia. Additionally, the European Commission granted orphan drug designation to alixorexton for the treatment of narcolepsy. Alkermes plc is a biopharmaceutical company focused on developing medical treatments.
